Top 10 Biotech companies that went public in 2013
Last year, when compiling the top 10 most outstanding biotech companies that initially placed shares on the market (initial public offerings, IPO) in 2012, we were lucky to score a full ten. In fact, there were even 11 of them and it looked very good compared to the meager period of 2008-2011. Only one company had to be excluded from the list. There were a lot more competitors on the list this year.
After several years of observing faint glimpses of investor interest in the high-risk biotech sector, we are now seeing stronger interest in acquiring shares than ever before. Companies set unusually high prices, and the stock prices of some of them literally soar on the day they appear on the market.
However, this trend is certainly not universal. Some of the biotech companies that launched IPOs this year had to lower their initial stock price. Some also failed to achieve outstanding results after their debut. At least one company, Prosensa ($RNA), which received the title of "Fierce 15 company 2012" and won the nomination "breakthrough in therapy" announced by the US Food and Drug Administration, is a clear example of what the wrong direction taken in clinical practice can lead to.
Discussions are periodically held about the differences between biotech companies from other market sectors and visible signs of their inflated value. Market trends are certainly repeating themselves. In the stock market, the past inevitably turns out to be a prerequisite for the new. And some of today's trendy biotech trends can quickly turn into tomorrow's flared jeans and hula hoops, as well as a couple of Ford Pinto.
Below are 10 companies that have repeatedly provided large revenues to sponsors and performers. The selection of companies used a combination of prices for shares initially placed on the market, compared with the price range, as well as the amount of funds raised and the subsequent increase in the value of shares. The list is somewhat subjective, and comments from readers about the list itself and the companies you would like to see in it are highly welcome.
In other words, you can consider this list a sketch of the current state of affairs in determining the fashionable biotechnological trends of 2013. After 20 years, you can look back and see the floor of the first floor or the elevator doors opening directly into the elevator shaft.
- Epizyme
- Foundation Medicine
- Portola Pharmaceuticals
- Ophthotech
- Agios Pharmaceuticals
- MacroGenics
- Receptos
- Bluebird bio
- Stemline
- Aratana Therapeutics
Nowhere does the old Latin definition of "caveat emptor" (let the buyer be vigilant) better illustrate the situation than in the biotech sector. This year, the revenues were very large. The risks were the same.
A new series of breakthroughs by biotech companies that initially placed shares on the market opens a busy fourth quarter season.
After a short summer lull in the arena of biotech companies that initially placed shares on the market, new companies registered with the Federal Securities and Exchange Commission of the United States come to the market at the beginning of the fourth quarter as the next generation of hopeful candidates who want to repeat the stellar debuts that many drug manufacturers expected this year.
Evgeniya Ryabtseva
Portal "Eternal youth" http://vechnayamolodost.ru based on FierceBiotech materials: The top 10 biotech IPOs of 2013.
25.10.2013